Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Intravesical Gemcitabine in BCG-Refractory Bladder CIS
NCT01259063Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2010
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in bladder carcinoma in situ (CIS), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2010; status: completed.
02
Drugs
everolimus
03
Conditions
bladder carcinoma in situ (CIS)
Beyond the preview
Go deeper on NCT01259063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01259063.